Valneva SE
VALN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001836564
No open-market purchases or sales by Valneva SE insiders were filed in the last 90 days; 20 institutions reported holding it in 13F filings for Q2 2026, worth $19.8M in total; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Valneva SE changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 8 | 10 | +2 |
| Shares | 263.4K | 115.4K | −148.0K (−56.2%) |
| Value | $8.27M | $6.43M | −$1.84M (−22.2%) |
New holders (4)
Institutions that held Valneva SE at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alps Advisors Inc | 60,338 | $3.37M | 0.04% |
| AlphaMark Advisors, LLC | 100 | $6.00K | 0.00% |
| Royal Bank of Canada | 22 | $1.00K | 0.00% |
| Bell Investment Advisors, Inc | 26 | $1.00K | 0.00% |
Sold out (2)
Institutions that held Valneva SE at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Vivo Capital, LLC | 200,000 | $6.28M |
| Granite Point Capital Management, L.P. | 11,982 | $376.0K |